Skip to main content
新芝生物 logo

新芝生物 — Investor Relations & Filings

Ticker · 920685 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2023-04-26 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920685

About 新芝生物

https://www.scientz.com/

Scientz Biotechnology specializes in the design and manufacture of high-performance life science instruments and laboratory equipment. The product range features ultrasonic cell disruptors, freeze dryers, gene guns, and high-pressure homogenizers, which are essential for sample preparation, cell lysis, and genetic engineering. The company also provides specialized solutions for tissue grinding, ultrasonic cleaning, and precise temperature control. These instruments serve a broad spectrum of applications in molecular biology, pharmaceutical research, environmental science, and agricultural technology. By integrating advanced ultrasonic and cryogenic technologies, Scientz supports research institutions and industrial laboratories in achieving accurate and reproducible results across various scientific disciplines.

Recent filings

Filing Released Lang Actions
2022年年度报告业绩说明会预告公告
Investor Presentation Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2022 Annual Report. It references the 2022 Annual Report already published on April 24, 2023, and invites investors to participate in an online meeting on May 5, 2023, to discuss the report's details. The document does not contain the actual annual report or detailed financial data but serves as an announcement for the upcoming investor presentation event focused on the annual report. Given the short length (1178 characters) and the nature of the content (announcement of a meeting to explain the annual report), this fits the category of an Investor Presentation (IP) announcement rather than the Annual Report itself or a Report Publication Announcement (RPA).
2023-04-26 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "宁波新芝生物科技股份有限公司 2023 年第一季度报告" which translates to "Ningbo New Gene Biotechnology Co., Ltd. 2023 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the first quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period January to March 2023. It is not an announcement or a brief summary but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-26 Chinese
第八届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Ningbo New Zhi Biotechnology Co., Ltd. regarding the approval of the company's 2023 first quarter report. It references the actual quarterly report published separately on the Beijing Stock Exchange information disclosure platform. The document itself does not contain the financial statements or substantive financial data but rather the Supervisory Board's review and approval of the quarterly report. The document length is short (1164 characters) and serves as an announcement of the meeting resolution and approval, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement of supervisory board resolutions and report approval, rather than the Interim/Quarterly Report (IR) which would contain the actual financial data.
2023-04-26 Chinese
第八届董事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from Ningbo New Zhi Biotechnology Co., Ltd. It details the convening and attendance of the eighth board's fourth meeting, including the approval of the company's 2023 first quarter report. The document references the actual quarterly report published separately on the Beijing Stock Exchange information disclosure platform, indicating this document is not the report itself but an announcement of the board meeting resolution approving that report. The document length is short (915 characters), and it does not contain substantive financial data or analysis, only the meeting details and voting results. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a formal announcement of board resolutions and meeting details rather than the quarterly report itself or a detailed management discussion.
2023-04-26 Chinese
关于治理专项自查及规范活动相关情况的报告
Governance Information Classification · 95% confidence The document is a detailed report from Ningbo Xinzhi Biotechnology Co., Ltd. regarding a special self-inspection and standardization activity related to corporate governance. It includes comprehensive information about the company's governance structure, internal systems, board and management composition, decision-making procedures, and compliance with relevant laws and regulations. The content focuses on governance practices, internal controls, and compliance rather than financial results or audit opinions. There is no indication that this is an annual report, audit report, earnings release, or any other financial report. The document is not a brief announcement or a proxy solicitation but a substantive governance report. Therefore, the most appropriate classification is Governance Information (CGR).
2023-04-23 Chinese
2023-026 2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '2022 年年度报告摘要' which translates to '2022 Annual Report Summary' and is from 宁波新芝生物科技股份有限公司 (Ningbo Scientz Biotechnology Co., Ltd). It contains detailed financial data for the year 2022, including assets, net profit, earnings per share, and shareholder information. It also includes management assurances about the accuracy of the report and mentions an unqualified audit opinion from a CPA firm. The document is over 6,000 characters, indicating it is substantive and not just an announcement. The content aligns with an official yearly report covering company activity and full financial performance, consistent with an Annual Report (10-K) type filing. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-04-23 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.